Gerhard Binder is associate professor and head of the Pediatric Endocrinology section in Tübingen (Germany) since 2008. He was trained by Michael Ranke (Tübingen) and John Parks (Atlanta/Georgia). His major interests are growth hormone deficiency, GH treatment, syndromic short stature, panhypopituitarism and disorders of puberty. He described GH1 splice site mutations causing dominantly transmitted isolated GHD, proposed GH treatment for short children with SHOX deficiency, established the measurement of GH content in newborn screening cards for early diagnosis of severe inborn GHD and discovered genomic IGF2 mutations and described the phenotype. He has published 195 peer-reviewed original papers. He is head of the German Working Group on Growth within the German Society for Pediatric Endocrinology and Diabetology.
Gerhard Binder created and sponsored an RCT with the drug DHEA in 2007 (J Clin Endocrinol Metab 2009; 94:1182). He was principal investigator for two long-acting GH trials in the near past.